Tiotropium Respimat Inhaler and the Risk of Death in COPD

• Published in: The New England journal of medicine Vol. 369; no. 16; pp. 1491 - 1501
• Main Authors: Wise, Robert A, Anzueto, Antonio, Cotton, Daniel, Dahl, Ronald, Devins, Theresa, Disse, Bernd, Dusser, Daniel, Joseph, Elizabeth, Kattenbeck, Sabine, Koenen-Bergmann, Michael, Pledger, Gordon, Calverley, Peter
• Format: Journal Article
• Language: English
• Published: Waltham, MA Massachusetts Medical Society 17.10.2013
• Subjects: Administration, Inhalation; Aged; Aged, 80 and over; Aqueous solutions; Biological and medical sciences; Bronchodilator Agents - administration & dosage; Bronchodilator Agents - adverse effects; Chronic obstructive pulmonary disease; Chronic obstructive pulmonary disease, asthma; Clinical trials; Confidence intervals; Coronary artery disease; Death; Double-Blind Method; Drug therapy; Female; Forced Expiratory Volume; General aspects; Heart diseases; Humans; Inhalation; Inhalers; Kaplan-Meier Estimate; Lung diseases; Male; Medical sciences; Middle Aged; Mortality; Nebulizers and Vaporizers; Obstructive lung disease; Patients; Pneumology; Pulmonary Disease, Chronic Obstructive - drug therapy; Pulmonary Disease, Chronic Obstructive - mortality; Risk; Safety; Scopolamine Derivatives - administration & dosage; Scopolamine Derivatives - adverse effects; Spirometry; Tiotropium Bromide; Delivery system; Lung disease; Prognosis; Respiratory disease; Tiotropium bromide; Bronchodilator; Mortality; Medicine; Anticholinergic agent; Risk factor; Inhaler; Bronchus disease; Chronic obstructive pulmonary disease

This large trial involving patients with chronic obstructive pulmonary disease examined the relative safety of tiotropium inhalation delivered by two different devices. No significant differences in mortality were noted between the two devices. Tiotropium (Spiriva, Boehringer Ingelheim), a long-acti...